tbuckley/cabot-search huggingface dataset:
Abstract P2-13-11: Assessing the impact of post-surgery areola repigmentation and 3-dimensional nipple tattoo procedures on body image and quality of life among medically underserved breast cancer survivors
Authors: NJ Burke, F Orenstein, T Napoles, S Chaumette, J Luce
Journal: Cancer Research (2016)

Abstract Background: The benefits of 3D nipple tattooing include restoration of a natural looking breast as well as the avoidance of additional surgeries to create a breast that more closely resembles its pre-surgical appearance. 3D nipple tattooing forms part of completion of the physical reconstruction process, offers women opportunity for a greater sense of closure around the loss of their breast, and plays an important role in helping a woman feel "whole again" physically, sexually and emotionally. The project's aim was to evaluate the experience of 3D-nipple/areola tattooing for medically underserved women who have undergone breast reconstruction and remain without a nipple or areola. Methods: In-depth interviews were conducted with 20 women who had undergone 3D-nipple/areola tattooing. Interviews were conducted in English and Spanish, recorded, translated and transcribed into English for analysis. Two research team members coded all interview transcripts and the research team met monthly to discuss emergent themes. Results: Interview narratives addressed the often unexpected impact 3D nipple-tattooing had on body image, self-esteem, emotional well-being, intimacy, and inter-personal relationships. Women described their decision-making processes as weighing concern about the needle, the pain, and the uncertainty of the outcome with the opportunity for returning to a more 'normal' appearance. Women also discussed the impact of the experience on their survivorship and sexuality in positive ways. Conclusions: 3-D nipple and/or areola tattooing is an acceptable and meaningful reconstruction process for medically underserved public hospital patients. The decision to undergo 3-D nipple and /or areola tattooing can be complex and is impacted by a women's surgical history and outcomes. The emotional response and positive impacts of the tattooing on body image and self-esteem illustrate the value of the procedure in the context of women's lives. Citation Format: Burke NJ, Orenstein F, Napoles T, Chaumette S, Luce J. Assessing the impact of post-surgery areola repigmentation and 3-dimensional nipple tattoo procedures on body image and quality of life among medically underserved breast cancer survivors. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-13-11.
Abstract A56: Inhibition of Snail-induced EMT promotes anti-tumor immune response in ovarian cancer.
Authors: Mana Taki, Kaoru Abiko, Noriomi Matsumura, Tsukasa Baba, Junzo Hamanishi, Naoki Horikawa, Ikuo Konishi
Journal: Clinical Cancer Research (2016)

Abstract Background: Peritoneal dissemination is a common mode of tumor progression in ovarian cancer, and one of the most important unfavorable prognostic factors. Epithelial-mesenchymal transition (EMT) has been indicated to be a key process in tumor invasion and metastasis. Recent studies demonstrate that EMT suppresses anti-tumor immunity in some types of cancer. The aim of the current study is to elucidate the relationship between EMT-related gene Snail and local immunity in ovarian cancer. Methods: The expression of Snail and patient survival was analyzed in two microarray datasets, TCGA, and KOV75 (75 ovarian cancer cases operated in our department). Using mouse ovarian cancer cell line HM-1, the influence of Snail expression on EMT, peritoneal dissemination, survival, and local immunity was analyzed using both in vitro and in vivo models. Snail-silenced cell line, HM1-sh-snail was established, and compared with the control HM-1. Results: Among 4 subtypes of high grade serous ovarian cancer, Mesenchymal subtype, which show marked stromal reaction in histopathology, shows the worst prognosis (TCGA, KOV75). Snail expression was significantly high in Mesenchymal subtype (TCGA, p&amp;lt;0.0001; KOV75, p&amp;lt;0.05). High Snail expression was significantly related to short overall survival in TCGA (p&amp;lt;0.05). In HM1-sh-snail, expression of vimentin and fibronectin was decreased in RT-PCR analysis. Cell migration was inhibited in wound-healing assay (p&amp;lt;0.001), but the cell proliferation was not altered in WST assay. In mouse peritoneal dissemination model, HM1-sh-snail group demonstrated longer survival than the control group (p&amp;lt;0.05). In mouse subcutaneous tumor model, HM-1-sh-snail group revealed smaller tumor than the control group (p&amp;lt;0.05), although there was no difference between two groups in nude mouse model. Flow cytometric analysis of mouse tumors revealed that infiltration of CD4+ T cells and CD8+ T cells were all increased and MDSCs were decreased in HM1-sh-snail group. Conclusion: Snail-induced EMT inhibits local immune reaction and promotes peritoneal dissemination in ovarian cancer. Snail may be a potential therapeutic target in ovarian cancer. Citation Format: Mana Taki, Kaoru Abiko, Noriomi Matsumura, Tsukasa Baba, Junzo Hamanishi, Naoki Horikawa, Ikuo Konishi. Inhibition of Snail-induced EMT promotes anti-tumor immune response in ovarian cancer. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; Oct 17-20, 2015; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(2 Suppl):Abstract nr A56.
Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic
Authors: M J Sernyak, R A Griffin, R M Johnson, H R Pearsall, B E Wexler, S W Woods
Journal: American Journal of Psychiatry (1994)

The authors examined continued neuroleptic exposure following inpatient treatment of mania with neuroleptics and lithium through structured chart review of 40 consecutive patients. At discharge, patients were receiving a mean of 793 mg/day (SD = 695) chlorpromazine equivalents; 6 months later they were receiving a mean of 634 mg/day (SD = 684). This decrease was statistically significant, but the patients' ongoing neuroleptic exposure remained substantial.
Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival
Authors: E Muchtar, A Dispenzieri, S K Kumar, F K Buadi, M Q Lacy, S Zeldenrust, S R Hayman, N Leung, T V Kourelis, W Gonsalves, R Chakraborty, S Russell, D Dingli, J A Lust, Y Lin, P Kapoor, R Go, R A Kyle, S V Rajkumar, M A Gertz
Journal: Leukemia (2016)
Hematopoietic stem cells develop in the absence of endothelial cadherin 5 expression
Authors: Heidi Anderson, Taylor C. Patch, Pavankumar N. G. Reddy, Elliott J. Hagedorn, Peter G. Kim, Kathleen A. Soltis, Michael J. Chen, Owen J. Tamplin, Maike Frye, Glenn A. MacLean, Kathleen Hübner, Daniel E. Bauer, John P. Kanki, Guillaume Vogin, Nicholas C. Huston, Minh Nguyen, Yuko Fujiwara, Barry H. Paw, Dietmar Vestweber, Leonard I. Zon, Stuart H. Orkin, George Q. Daley, Dhvanit I. Shah
Journal: Blood (2015)
Abstract P3-14-04: Effects of the dual selective CYP17 lyase inhibitor and androgen receptor (AR) antagonist, VT-464, on AR+ and ER+ tumor models in vitro and in vivo
Authors: SJ Ellison, JD Norris, S Wardell, JR Eisner, WJ Hoekstra, DB Stagg, HM Alley, WR Moore, DP McDonnell
Journal: Cancer Research (2016)

Abstract VT-464 is a lyase-selective inhibitor of the dual-activity CYP17A1 enzyme that is required for the synthesis of androgens and estrogens in the gonads, adrenals, and tumors. In addition to its role as a CYP17A1 lyase inhibitor, we previously showed that VT-464 also functions as a direct and effective AR antagonist in prostate cancer models. In our current study, we evaluated the therapeutic potential of VT-464 in breast cancer by analyzing its effectiveness in several AR-positive breast cancer cell lines, including those that are ER-positive and ER-negative. Through in vitro assays and xenograft analysis, we compared the activity of VT-464 to enzalutamide, a second generation AR antagonist that is approved for the treatment of castration resistant prostate cancer and is in multiple Phase 2 breast cancer studies. Our results showed that VT-464 was highly effective in preventing proliferation of both ER-positive and ER-negative breast cancer cell lines in vitro. Importantly, significant inhibition was also observed in soft agar assays that assesses anchorage-independent growth. In mechanistic studies, VT-464 and enzalutamide both inhibited induction of AR target genes and recruitment of AR to target promoters, verifying direct AR antagonistic activity observed previously in prostate cancer cells. Furthermore, we evaluated the ability of VT-464 and enzalutamide to inhibit tumor formation in a tamoxifen-resistant model of breast cancer. Oral administration of either enzalutamide or VT-464 significantly decreased tumor growth in mice, with VT-464 achieving greater growth inhibition than enzalutamide. Together, these data provide further rationale for the future study of the AR as a viable therapeutic target in breast cancer, and importantly, suggest that AR inhibition can impact tamoxifen-resistant tumor growth. The dual effects of CYP17A1 lyase inhibition and AR antagonism that are achieved with VT-464 further supports its development as an effective oral therapy option for AR-positive breast cancer. A phase 1 / 2 clinical study of oral VT-464 in women with AR+ triple-negative breast cancer or ER+ cancer resistant to aromatase inhibitors will commence in 2015. Citation Format: Ellison SJ, Norris JD, Wardell S, Eisner JR, Hoekstra WJ, Stagg DB, Alley HM, Moore WR, McDonnell DP. Effects of the dual selective CYP17 lyase inhibitor and androgen receptor (AR) antagonist, VT-464, on AR+ and ER+ tumor models in vitro and in vivo. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-14-04.
Frequent HLA class I and DP sequence mismatches in serologically (HLA- A, HLA-B, HLA-DR) and molecularly (HLA-DRB1, HLA-DQA1, HLA-DQB1) HLA- identical unrelated bone marrow transplant pairs
Authors: P Santamaria, NL Reinsmoen, AL Lindstrom, MT Boyce-Jacino, JJ Barbosa, AJ Faras, PB McGlave, SS Rich
Journal: Blood (1994)
Tumor-Damaging Activity in Plant Families Showing Antimalarial Activity. Amaryllidaceae
Authors: D. B. Fitzgerald, J. L. Hartwell, J. Leiter
Journal: JNCI Journal of the National Cancer Institute (1958)

Tumor-Damaging Activity in Plant Families Showing Antimalarial Activity. Amaryllidaceae D. B. Fitzgerald, D. B. Fitzgerald Laboratory of Chemical Pharmacology, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar J. L. Hartwell, J. L. Hartwell Laboratory of Chemical Pharmacology, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar J. Leiter J. Leiter Laboratory of Chemical Pharmacology, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar 2National Institutes of Health, Public Health Service, U. S. Department of Health, Education, and Welfare. Author Notes JNCI: Journal of the National Cancer Institute, Volume 20, Issue 4, April 1958, Pages 763–774, https://doi.org/10.1093/jnci/20.4.763 Published: 01 April 1958 Article history Received: 22 October 1957 Published: 01 April 1958
Giant Cystic Meconium Peritonitis
Authors: Y S Rao, T V Murthy
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract A34: Activation-induced cytidine deaminase links ovulation-induced inflammation and serous carcinogenesis.
Authors: Stav Sapoznik, Keren Bahar-Shany, Hadar Brand, Yishay Pinto, Orshay Gabay, Efrat Glick-Saar, Chen Dor, Oranit Zadok, Iris Barshack, Adi Zundelevich, Einav Nili Gal-Yam, Yuval Yung, Ariel Hourvitz, Jacob Korach, Mario Beiner, Jasmine Jacob, Erez Y. Levanon, Michal Barak, Sarit Aviel-Ronen, Keren Levanon
Journal: Clinical Cancer Research (2016)

Abstract In recent years, the notion that serous ovarian carcinoma results from ovulation-induced inflammation of the fallopian tube epithelial cells (FTECs) has gained evidence. However, the mechanistic pathway that leads to mutagenesis and genomic instability has not been revealed yet. The mutator enzyme activation-induced cytidine deaminase (AID), which is known to be involved in the process of immunoglobulin somatic hypermutations, has also been recently implicated in inflammation-induced epithelial malignancies. In the current study, we propose that AID is a mechanistic link between ovulation-induced inflammation in FTECs and the genotoxic damage that leads to serous carcinogenesis. We tested at the expression of AID in human fallopian tube tissues from patients with various gynecological pathologies, as well as in cultured FTECs in an experimental model mimicking normal ovulation. We also looked at the functional effects of AID up regulation in vitro by analyzing double strand DNA breaks, abasic sites, hypomethylation and chromosomal rearrangements. We also performed a comprehensive bioinformatic analysis of somatic mutations patterns in publically available serous carcinoma sequencing data in search of AID mutational fingerprints. We show that AID, previously shown to be functional only in B lymphocytes, is expressed in human FTECs under physiological conditions, is induced in vitro upon ovulatory-like stimulation and is elevated in vivo under carcinogenesis-associated circumstances. We also report that AID activity results in epigenetic, genetic and genomic damage in FTECs. Overall, our data provides new insights on the etiology of serous ovarian carcinogenesis and may set the ground for innovative approaches aimed at prevention and early-detection. Citation Format: Stav Sapoznik, Keren Bahar-Shany, Hadar Brand, Yishay Pinto, Orshay Gabay, Efrat Glick-Saar, Chen Dor, Oranit Zadok, Iris Barshack, Adi Zundelevich, Einav Nili Gal-Yam, Yuval Yung, Ariel Hourvitz, Jacob Korach, Mario Beiner, Jasmine Jacob, Erez Y. Levanon, Michal Barak, Sarit Aviel-Ronen, Keren Levanon. Activation-induced cytidine deaminase links ovulation-induced inflammation and serous carcinogenesis. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; Oct 17-20, 2015; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(2 Suppl):Abstract nr A34.
New US food labels reflect modern serving sizes and added sugar
Authors: Michael McCarthy
Journal: BMJ (2016)

Packaged foods in the US will soon bear new, easier to read nutrition labels that will reflect more closely the average serving sizes Americans eat and provide information about the amount of sugars that are added to processed foods, the US Food and Drug Administration (FDA) announced 20 May.1 The revisions are the first significant changes to US food labels in more than 20 years.

The new labels look similar to the old ones but the type size of “calories,” “servings per container,” and the “serving size” declaration will be larger and the number of calories and serving sizes will be in bold.

The label’s footnote explaining the meaning of percent daily value will be simplified from the current wording of “percent daily values are based on a 2000 calorie diet. Your daily value may be higher or lower depending on your calorie needs” to “the % daily value tells you how much a nutrient in a serving …
Comparison of three systems for diagnosing borderline personality disorder
Authors: H F Nelson, H Tennen, A Tasman, M Borton, M Kubeck, M Stone
Journal: American Journal of Psychiatry (1985)

The authors assessed three systems for diagnosing borderline personality disorder: DSM-III, the checklist criteria of Spitzer et al., and the Diagnostic Interview for Borderline Patients. In an inpatient sample of 51 patients, 43 (84%) met the criteria of at least one of these systems; analyses were carried out on 28 of these patients. Twelve (43%) of these 28 patients met criteria for all three systems, seven (25%) for two systems, and nine (32%) for only one system. Kernberg's structural criteria showed reasonable overlap with the other diagnostic criteria. Affective disorders were prominent across diagnostic measures in this sample of borderline patients.
Abstract B40: Prediagnosis leukocyte telomere length and risk of ovarian cancer.
Authors: Meng Yang, Jennifer Prescott, Elizabeth M. Poole, Megan S. Rice, Annika Idahl, Eva Lundin, Immaculata De Vivo, Shelley S. Tworoger
Journal: Clinical Cancer Research (2016)

Abstract Introduction: Ovarian cancer is characterized by substantial genomic instability. Telomeres, which protect the physical integrity of chromosomes, are shortened by each cell division, and evidence supports that longer telomeres may reduce genomic instability. While retrospective studies generally support an inverse association of telomere length and ovarian cancer risk, the measures of telomere length after diagnosis may be influenced by treatment. Therefore, we examined the relationship between leukocyte telomere length (LTL) assessed prior to diagnosis and risk of ovarian cancer in three prospective studies. Methods: We used buffy coat samples collected from healthy participants in the Nurses' Health Study (NHS), NHSII, and the Northern Sweden Health and Disease Study (NSHDS). Women who later developed ovarian cancer were matched to one or two controls on age, menopausal status, and date of blood collection. LTL was assessed using quantitative PCR-based assays in 5 batches with coefficients of variation of 10-15%. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using conditional logistic regression, based on study-specific quartiles in controls, for each study separately. We used fixed-effects models for meta-analysis. Multivariate models adjusted for oral contraceptive use, tubal ligation, family history of ovarian cancer, parity, smoking status, and body mass index. Results: In total, there were 487 cases and 810 controls across the three studies. The mean age at blood collection ranged from 45 (NHSII) to 57 (NHS) years. In unadjusted and multivariate models, we observed a suggestion of an inverse association between LTL and ovarian cancer risk in each study, although none of the trend tests were statistically significant. In a meta-analysis of the multivariate adjusted models, women in the longest versus shortest quartile of LTL had a non-significant 26% lower risk of ovarian cancer (OR=0.74; 95%CI=0.49-1.12; p-trend=0.33). Conclusion: In this first prospective study of telomere length and ovarian cancer risk, we observed that longer leukocyte telomere length was suggestively associated with lower ovarian cancer risk. Given that serous tumors are more likely to exhibit genomic instability, we are currently evaluating the association for this subtype as well as conducting pooled analyses with common quartile cut points across studies. Citation Format: Meng Yang, Jennifer Prescott, Elizabeth M. Poole, Megan S. Rice, Annika Idahl, Eva Lundin, Immaculata De Vivo, Shelley S. Tworoger. Prediagnosis leukocyte telomere length and risk of ovarian cancer. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; Oct 17-20, 2015; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(2 Suppl):Abstract nr B40.
Irish medical school in Bahrain may breach human rights law
Authors: Anne Gulland
Journal: BMJ (2016)

A human rights organisation has claimed that the Irish government has breached human rights law by giving accreditation to a medical campus in Bahrain, operated by the Royal College of Surgeons in Ireland (RSCI).

The Global Legal Action Network made a submission to the United Nations Human Rights Council (UNHRC) to highlight concerns over the unconditional accreditation given to the RCSI-Bahrain campus by the Irish Medical Council.

It said that the Irish state was in breach of international law because of the “occurrence of serious human rights violations, including torture” in the training hospitals used by RCSI-Bahrain. The UNHRC does not take action over written submissions so the network is now considering going to the UN’s special rapporteur on torture.

The college opened its medical campus in Bahrain in 2004. It continued the partnership despite political …
Joint Effusions and Flexion Deformities
Authors: J C FAVREAU, C A LAURIN
Journal: JAMA (1963)

The etiology of flexion deformities was studied experimentally on infant and adult cadavers. The experiment was performed on all major joints, which were first filled with liquid under tension and later connected to a manometer. The influence of joint position on the intra-articular pressure was then carefully noted. It was consistently observed that the position of least pressure was always a position of slight flexion. It was therefore concluded that the occurrence of flexion deformities in the presence of effusion is due to maintenance of the position of comfort, since it is in this position that periarticular structures are under least pressure.
Misleading thoracic Ga-67 uptake caused by splenic displacement.
Authors: H Bernstine, Z Bar-Sever, M Cohen, R Hardoff
Journal: Clinical Nuclear Medicine (2001)

BERNSTINE, HANNA M.D., M.Sc.; BAR-SEVER, ZVI M.D.; COHEN, MAYA M.D.; HARDOFF, RUTH M.D., Sc. Author Information
Nonpayment for preventable infections in U.S. hospitals.
Authors: Kevin T Kavanagh
Journal: New England Journal of Medicine (2013)

To the Editor: Lee et al. (Oct. 11 issue)1 found that the penalty imposed by the Centers for Medicare and Medicaid Services (CMS) of nonpayment for health care–acquired conditions did not result in a significant lowering of infection rates. This finding furthers the evidence that line-item penalties applied to a predominantly bundled payment system result in little change in quality. Medicare uses a diagnosis-related group (DRG) payment system, which for most DRGs allows an increase in reimbursement if a “comorbidity” or “major comorbidity” diagnosis exists. However, maximum reimbursement can still often be achieved even in the face of a health care– acquired condition by billing with the use of codes for a different coexisting diagnosis. During the first year after implementation of the CMS policy of nonpayment for health care–acquired conditions, only $18.8 million was recouped from hospitals nationwide; of this amount, only $85,254 was for vascular catheter-associated infections.2 The Commonwealth Fund has also reported that this initiative did not produce a major change in care practices in safety-net hospitals.3 For valuebased purchasing initiatives to improve quality, not only must meaningful metrics be used, but also considerable financial penalties and rewards must exist.4